Author

Alysha K. Kadva

Observed names: Alysha Kadva, Kadva, Alysha

Institution: BeOne Medicines (Switzerland)

Observed institutions: Genentech, BeOne Medicines (Switzerland)

ORCID: 0000-0002-2637-8373

Observed ORCID: 0000-0002-2637-8373

OpenAlex ID: A5084867240

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial

2017 · Gerd R Burmester, William F Rigby, et al. · Annals of the Rheumatic Diseases · 82

First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

2025 · Jianming Xu, Ken Kato, et al. · Advances in Therapy · 14

Abstract P225: Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

2021 · David S. Hong, Daniel Catenacci, et al. · Molecular Cancer Therapeutics · 10

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

2021 · Wenhui Zhang, Astrid Scalori, et al. · Inflammatory Bowel Diseases · 10

A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study

2014 · Fabrizio De Benedetti, Nicolino Ruperto, et al. · Arthritis & Rheumatology · 10

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

2025 · Markus Moehler, Do-Youn Oh, et al. · Advances in Therapy · 9

Efficacy and Safety of Anti-PD-(L)1 Treatments: A Systematic Review and Meta-analysis of Asian vs Non-Asian Patients With Esophageal Squamous Cell Carcinoma

2025 · Jaffer Ajani, Lin Zhan, et al. · Gastro Hep Advances · 2

Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers

2025 · Caicun Zhou, Rose Huang, et al. · The Oncologist · 2

Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.

2025 · Longqi Chen, Yongde Liao, et al. · Journal of Clinical Oncology · 1

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

2022 · Wenhui Zhang, Astrid Scalori, et al. · Inflammatory Bowel Diseases · 1

06. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis

2017 · Shazad Jafri, Athimalaipet V. Ramanan, et al. · Rheumatology · 1

Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

2024 · Caicun Zhou, Tim Meyer, et al. · Journal of Clinical Oncology

P035 Defining Responders for the Crohn’s Disease Patient-Reported Outcomes Signs and Symptoms (CD-PRO/SS) Tool Using Data From Patients Treated With Etrolizumab

2019 · Peter Higgins, Kendra DeBusk, et al. · The American Journal of Gastroenterology

Works count: 15

Citation count: 142

H-index: 6

I10-index: 5